NBIX - Neurocrine Biosciences Q3 2021 Earnings Preview

Neurocrine Biosciences (NASDAQ:NBIX) is scheduled to announce Q3 earnings results on Monday, November 1st, after market close. The consensus EPS Estimate is $0.81 (-16.5% Y/Y) and the consensus Revenue Estimate is $297.32M (+15.0% Y/Y). Canaccord Genuity lowered the recommendation on Neurocrine to hold from buy, citing the need for a better entry point on uncertain sales prospects for the company’s lead revenue generator Ingrezza, in August. In August, Seeking Alpha contributor Stephen Simpson argued that "while Neurocrine has a promising pipeline, major data isn't coming soon and the Street wants to see Ingrezza back on a reliable growth path before returning to the stock". Over the last 2 years, NBIX has beaten EPS estimates 50% of the time and has beaten revenue estimates 63% of the time. Over the last 3 months, EPS estimates have seen 8 upward revisions and 2 downward. Revenue estimates have seen 13 upward revisions and 5 downward.

For further details see:

Neurocrine Biosciences Q3 2021 Earnings Preview